Aug 24, 2014 12:49 PM

Roche to buy US biotech firm InterMune for $8.3B

The Associated Press

BERLIN (AP) Swiss pharmaceutical company Roche says it will buy a California-based developer of treatments for lung diseases, InterMune Inc., in a deal worth $8.3 billion.

Roche said Sunday the companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share. That's a premium of 38 percent over InterMune's closing price on Friday.

The Swiss firm says the acquisition the biotechnology company, based in Brisbane, California, "will allow Roche to broaden and strengthen its respiratory portfolio globally."


--  Dealing with the Disease of Addiction? Click here for help --

More from

NH1 News Debates
NH1 News Replay

NH1 on Twitter

NH1 SkyView Cameras

NH1 on Facebook

Check out NH1 News Rail Polls on LockerDome on LockerDome